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Abstract 
Aims: The aim of this study was to explore the correlation of hTERT splice 
variant expression with MCPH1/BRIT1 and BRCA1 expression in epithelial 
ovarian cancer (EOC) samples.  
Background: Telomerase activation can contribute to the progression of 
tumours and the development of cancer. However, the regulation of 
telomerase activity remains unclear. MCPH1 (also known as BRIT1, BRCT-
repeat inhibitor of hTERT expression) and BRCA1 are tumor suppressor 
genes that have been linked to telomerase expression.  
Methods: qPCR was used to investigate telomerase splice variants, 
MCPH1/BRIT1 and BRCA1 expression in EOC tissue and primary cultures.  
Results: The wild type Įȕ hTERT variant was the most common splice 
variant in the EOC samples, followed by Įȕ- hTERT, a dominant negative 
regulator of telomerase activity. EOC samples expressing high total hTERT 
demonstrated significantly lower MCPH1/BRIT1 expression in both tissue 
(p=0.05) and primary cultures (p=0.03). We identified a negative correlation 
between MCPH1/BRIT1 and Įȕ hTERT (p=0.04), and a strong positive 
association between MCPH1/BRIT1 and both Į-/ȕ hTERT and Į-/ȕ- hTERT 
(both p=0.02). A positive association was observed between BRCA1 and Į-
/ȕ hTERT and Į-/ȕ- hTERT expression (p=0.003 and p=0.04, respectively).  
Conclusions: These findings support a regulatory effect of MCPH1/BRIT1 
and BRCA1 on telomerase activity, particularly the negative association 
between MCPH1/BRIT1 and the functional form of hTERT Įȕ).   
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1. Introduction 
Telomeres are regions of repetitive nucleotide sequences at each end 
of a chromatid. Their function is to preserve genome stability by constructing 
protein-DNA complexes containing TRF1, TRF2, POT1, Rap1, and TPP1. 
This complex, known as the shelterin complex, is critical for both the 
maintenance and function of the telomere [1]. In humans, telomeres are 
composed of a highly repetitive (1000-2000 times) hexameric TTAGGG 
sequence. In somatic cells, the telomere gets shorter with each cell cycle 
because of the end replication problem [2].  
In germ cells, stem cells and cancer cells, telomerase ± a 
ribonucleoprotein enzyme ± offsets this shortening process by adding 
repetitive nucleotide sequences to the ends of the DNA, thus preventing 
damage to the chromosome ends. Telomerase consists of a number of sub-
units, including an RNA moiety (hTR), which is expressed universally, and a 
telomerase reverse transcriptase (hTERT). hTERT is composed of 16 exons, 
which results in a mRNA transcript of approximately 4 kb [3].  
Alternative splicing of hTERT has been shown to affect telomerase 
activity. To date, fourteen alternative splice variants have been identified, the 
most common variants being ĮȕDQGȖ deletions. These variations contribute 
to a range of different disease-specific transcripts [4-7]. Splice variants have 
been identified in a variety of tumors, including thyroid [8], gastrointestinal 
system tumors [9] and myelodysplastic syndromes [10]. The Į-ȕ splice 
variant results from a 36-bp in-frame deletion of exonic sequences in exon 6 
and the Įȕ- splice variant results from a 183-bp deletion in which exons 7 
and 8 are lost, resulting in a truncated protein. Splicing at these sites may 
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happen in combination or independently to create 3 alternatives from the full-
OHQJWKĮȕ:7Įȕ-Į-ȕDQGĮ-ȕ- [6].  
The activation of telomerase has also been shown to contribute to the 
progression of tumors and the development of cancer [11]. For example, 
increased telomerase activity has been detected in 92% of malignant ovarian 
tumors [12], and the activity of telomerase has been connected to survival 
rates and the aggressive development of ovarian tumors [13-14]. Telomerase 
activity has therefore been proposed as a marker for predicting ovarian 
cancer relapse following treatment with chemotherapy [13,15]. Furthermore, 
inhibition of telomerase activity in ovarian cancer cells inhibits cell growth and 
induces apoptosis [16]. Taking into account these findings, Meng and others 
have suggested using an inhibitor of telomerase activity, BIBR1532, combined 
with classic chemotherapy, to treat ovarian cancer [14].  
Telomerase activity has been shown to be regulated by the tumor 
suppressors MCPH1 and BRCA1 [17-18]. MCPH1, which was first identified 
as BRIT1 (BRCT-repeat inhibitor of hTERT expression) [17], interacts directly 
with the hTERT proximal promoter and inhibits hTERT expression, thus 
resulting in reduced telomerase activity [19]. 
This study has investigated the relationship of MCPH1/BRIT1 and 
BRCA1 with hTERT and hTERT splice variant expression in EOC tissue and 
primary cultures. MCPH1/BRIT1 and total hTERT expression displayed an 
inverse association. A positive association between MCPH1/BRIT1 and 
BRCA1 with Į-ȕ hTERT and Į-ȕ- hTERT was also identified. This study 
provides new insight into the tumor suppressor functions of MCPH1/BRIT1 
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and BRCA1, linking them with the inactivation of the functional form of hTERT 
and the activation of dominant negative splice variants of hTERT.  
 
2. Materials and Methods 
2.1 Sample collection and ethical approval 
Four ovarian cancer cell lines (OVCA433, SKOV-3, TR175, 1847) were 
obtained from Cancer Research UK, and 2 immortal primary EOC cultures 
were established from ascites samples from patients with high-grade EOC 
(1015-A1 and 1016-A1) as previously described [20]. Patient information and 
clinical data for 20 tissue samples used in this study (15 EOCs, 4 benign 
tumours and 1 normal ovarian sample from an adjacent tumor) and 40 
primary EOC cultures are presented in Supplementary Table 1. Ethical 
approval was obtained from the Local Research Ethics Committee of the 
Leeds Teaching Hospitals NHS Trust, Leeds, UK, (REC reference 
09/H1306/96).  
 
2.2 Cell culture 
Cells were maintained in 530,  *OXWDPD[ medium (DMEM) 
supplemented with 10% fetal calf serum (FCS), penicillin (100U/ml) and 
streptomycin (100µg/ml; Gibco Carlsbad, CA, USA). Cells were incubated in 
25±75 cm2 flasks under standard culture conditions in a 5% CO2 incubator at 
37°C.  
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2.3 Telomeric repeat amplification protocol (TRAP) assay 
Telomerase activity levels were measured using the TRAP assay. 
Harvested cells grown to 80-90% confluence in a 75cm2 flask were lysed in 
400µl of 1X CHAPS lysis buffer on ice for 30 min then spun at 12,000 g for 20 
PLQ DW Û& 7KH VXSHUQDWDQW ZDV VWRUHG LQ DOLTXRWV DW -Û& 7KH SURWHLQ
concentration was measured using the DC protein reagent set (BioRad, 
Hercules, CA, USA DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO $ O 3&5
reaction mixture containing 1 X TRAPEZE® XL Reaction Mix, 2 units 
TITANIUMTM Taq DNA polymerase (Clontech, Mountain View, CA, USA), and 
100 ng of protein extract was incubated at 30°C for 30 min. The PCR was 
performed with an ABI PRISM 7900 Sequence Detector System using the 
following conditions: 95°C for 2 min, followed by 45-cycle amplification (94°C 
for 15 seconds, 59°C for 1 min and 45°C for 35 seconds). A positive control 
containing 500 telomerase active cells was prepared for each assay. A 
negative control sample lacking telomerase, a no template control and heated 
negative controls for each sample were also included. The generated data 
were analyzed with 7900 sequence detector software (Version 1.2.3; PE 
Applied Biosystems, Carlsbad, CA, USA). The amount of telomerase activity 
was calculated based on a standard curve using TSR8 supplied in the kit. 
 
2.4 RNA extraction and reverse transcriptase reaction  
Frozen tissue samples were embedded in Optimal Cutting 
Temperature (OCT) embedding medium (Lamb Inc.) on cork discs. A Leica 
CM3050 S cryostat was used to cut the embedded tissue into 10±20ȝP
sections at -Û&7HQVHFWLRQV IURPHDFh sample were placed into a 1.5ml 
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Eppendorf tube. Tissue was washed twice with PBS to remove all OCT 
residues. RNA was extracted from frozen tissue samples, cell lines and 
primary EOC cultures using the TRIzolTM reagent according to the 
PDQXIDFWXUHU¶VSURWRFRO7LVVXHVDPSOHVZHUHUHVXVSHQGHG in 1ml of TRIzol 
reagent and homogenized on ice using a P200 pipette (Gilson, Middleton, WI, 
USA).  
 
2.5 Quantitative real-time PCR (qRT-PCR) 
Complementary DNA (cDNA) was used as the DNA template in PCR 
reactions. cDNA synthesis was performed using Superscript III (Invitrogen, 
Paisley, Scotland, UK). Briefly, a 14µl reaction contained 1500ng total RNA, 
1µg random hexamers, and 1µl dNTPs (10mMol) were heated to 65°C for 5 
min and cooled on ice for 2 min. 6µl of a master mix containing 4µl 5x first-
strand buffer, 1µl 0.1M dithiothreitol (DTT), and 1µl Superscript III (200 U/µl) 
was added and incubated at 25°C for 5 min before heating at 50°C for 50 min 
and finally at 70°C for 15 min. 
Duplicate real-time PCR analysis was performed using the ABI 7900 
sequence detection system (Applied Biosystems, Foster City, CA, USA) for 
both SYBR Green (MCPH1/BRIT1 and BRCA1 amplifications) and TaqMan 
reactions (hTERT amplification) [21-22]. The 36B4 gene was used as an 
endogenous control to normalize gene expression. Standard curves were 
performed using serial dilutions of cDNA from human fetal brain for 
MCPH1/BRIT1 amplification, normal human ovary (Clontech, Mountain View, 
CA, USA), for BRCA1, and human MCF7 breast adenocarcinoma cells for 
hTERT amplification. PCR reactions were carried out in a 96-well plate using 
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a 25µl reaction volume XVLQJWKHIROORZLQJFRQGLWLRQVPLQDWÛ&IROORZHG
E\PLQDWÛ&DQGF\FOHVRIGHQDWXUDWLRQDWÛ&IRUVHFRQGVDQG
DQQHDOLQJH[WHQVLRQDWÛ&IRUPLQ Total hTERT primers were designed to 
detect all splice variants types in one run. Details of the primer sequences for 
qRT-PCR are listed in Supplementary Table 2. Mann-Whitney (MW) tests 
were  performed to determine statistical significance. Kaplan-Meir survival 
curve analysis was performed followed by a false discovery rate detection 
ajustment generating q values due to the small sample size of the study  
requiring q<0.05 (95% confidence level) to be considered significant 
(GraphPad Prism 7). 
 
2.6 ([SUHVVLRQRIĮ-/ȕ hTERT  
7KH HIIHFW RI LQFUHDVHG Į-/ȕ hTERT expression on MCPH1/BRIT1 
expression was measured in the 4 ovarian cancer cell lines (OVCA433, 
SKOV-3, TR175, 1847) and human embryonic kidney HEK 293 cells (ATCC, 
Middlesex, Uk). $QĮ-ȕhTERT construct was kindly provided by Professor 
RR Reddel (Children's Medical Research Institute, University of Sydney, 
Australia) in the pIRESneo vector (Clontech) [23]. HEK 293 cells were seeded 
at 2 x 105 cells/ml and allowed to grow until 70±80% confluence, and then 
transfected using Lipofectamine 2000 (Invitrogen, USA) based on the 
PDQXIDFWXUHU
VSURWRFRO$UDWLRRI OLSRIHFWDPLQHWRĮ-/ȕ hTERT plasmid 
DNA concentration (µl/µg) was used after 48 hours. The expression levels of 
Į-ȕ hTERT and MCPH1/BRIT1 were evaluated using qRT-PCR as 
described above. 
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3. Results 
3.1 Expression profiles of total hTERT and hTERT splice variants in ovarian 
cancer cell lines  
Total hTERT and its splice variants were examined in the OVCA433, 
SKOV-3, TR175 and 1847 cell lines. Telomerase activity was detected in all 
lines, with levels ranging from 0.086 to 3.38 log10 TPG units. The relative 
expression of hTERT variants was evaluated as the percentage of each 
hTERT splice variant in relation to total hTERT expression (Fig. 1, 
Supplementary Table 3). 7KH H[SUHVVLRQ OHYHO RI Į-ȕ KTERT was higher 
than for other deletion splice variants (Fig. 1). We then investigated whether 
the expression levels of different hTERT splice variants were linked with 
telomerase activity; however, no statistically significant correlations were 
detected.  
We next measured hTERT expression in normal ovary as well as EOC 
tissue and primary EOC cultures. We did not detect any hTERT expression in 
the 5 benign or normal samples examined. By contrast, hTERT was detected 
in 60% (12/15) of EOC tissues and 52% (21/40) of cultured samples. Samples 
were classified as expressing high or low total hTERT based on the mean 
expression levels of EOC tissue (Fig. 2A) and primary cultures (Fig. 2B). We 
then examined the expression of the different hTERT VSOLFHYDULDQWVĮȕ
Į- ȕĮȕ- DQGĮ-ȕ 
All EOC tissue samples (12/12) and 81% of primary cultures (17/21) 
expressing total hTERT ZHUHDOVRSRVLWLYHIRUZLOGW\SHĮȕhTERT. The 
Įȕ- hTERT splice variant, a dominant negative regulator of telomerase 
activity, was identified in both EOC tissue (75%, 9/12) and primary cultures 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 11 
(86%, 18/21) expressing total hTERTĮ-ȕDQGĮ-ȕ- hTERT splice variants 
were detected in 50% (6/12) of EOC tissues (Fig. &7KHĮ-ȕ- hTERT splice 
YDULDQWZDVGHWHFWHGLQRISULPDU\FXOWXUHVDQGWKHĮ-ȕhTERT 
splice variant was detected in 38% (8/21) of primary cultures (Fig. 2D). All 
EOC tissue samples and primary cultures showed expression of at least 1 
splice variant, except for one. Although this expressed low levels of total 
hTERT, none of the 4 splice variants investigated here were detected.  
 
3.2 Expression profiles of MCPH1/BRIT1 and BRCA1  
The expression levels of both MCPH1/BRIT1 and BRCA1 were 
examined in normal ovary, EOC tissue and primary cultures. Samples were 
classified as high or low expressing based on the mean of the EOC tissues 
and primary cultures respectively. MCPH1/BRIT1 expression was detected in 
normal ovary and all EOC tissue samples and primary cultures. Ten of 17 
EOC tissue samples (59%) and 25/37 primary culture samples (68%) showed 
low MCPH1/BRIT1 mRNA expression (Fig. 2E and 2F). BRCA1 expression  
was detected in all EOC tissues (17/17) and 18/31 (58%) primary cultures. 
Ten of 17 (59%) and 14/18 (78%) patients expressed low BRCA1 in EOC 
tissues (Fig. 2G) and in primary cultures (Fig. 2H), respectively. 
 
3.3 Comparison of total hTERT with MCPH1/BRIT1 and BRCA1  
Samples were categorized into 3 groups (negative, low and high) 
based on expression levels of total hTERT, then correlated to the expression 
levels of MCPH1/BRIT1 and BRCA1. Unexpectedly, MCPH1/BRIT1 
expression was lower in total hTERT negative samples than that in samples 
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with low total hTERT and was similar to samples with high total hTERT 
(p=0.01) in EOC tissues (Fig. 3A). A similar trend was noted in primary 
cultures though this result was not significant (p=0.10). Investigation of 
MCPH1/BRIT1 mRNA expression in total hTERT positive EOC tissue 
samples revealed a significant inverse association between high total hTERT 
and low MCPH1/BRIT1 (p=0.05; Fig. 3A). A similar inverse association was 
observed in primary cultures (p=0.03; Fig. 3B).  
BRCA1 expression levels were comparable in EOC tissue samples 
with negative or low or high total hTERT expression (Fig. 3C). However, in 
primary cultures lower levels of BRCA1 were observed in samples with 
negative total hTERT compared to samples with positive total hTERT 
expression (p=0.04; Fig. 3D). 
 
3.4 Comparison of hTERT splicing variants with MCPH1/BRIT1 expression  
In EOC tissues, the correlation of hTERT splice variants with 
MCPH1/BRIT1 expression revealed a strong negative association between 
MCPH1/BRIT1 and WKH IXQFWLRQDO IRUP Įȕ hTERT, such that samples 
H[SUHVVLQJ KLJK Įȕ hTERT exhibited a reduction in MCPH1/BRIT1 
expression (p=0.04; Fig. 4A). High MCPH1/BRIT1 expression was  
associated with high levels of Į-ȕ(p=0.02; Fig. 4B) DQGĮ-ȕ- (p=0.02; Fig. 
4C) hTERT expression. There was no significant association between the 
Įȕ- hTERT variant and MCPH1/BRIT1 expression levels (data not shown).  
We also performed relative expression analysis, which has previously 
been used to interpret telomerase expression [24]. The percentage of each 
hTERT isoform was calculated in relation to the overall expression and then 
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correlated with MCPH1/BRIT1 expression. Samples with low MCPH1/BRIT1 
expression expressed H[FOXVLYHO\ĮȕhTERT RUĮȕDQGĮȕ- hTERT, 
whereas Į-ȕRUĮ-ȕ- hTERT or both were detected in high MCPH1/BRIT1-
expressing samples only (Fig. 4D). A high percentage Įȕ hTERT was 
identified in low MCPH1/BRIT1 expression samples (p=0.01; Fig. 4E). No  Į-
ȕRUĮ-ȕ- hTERT expression was detected in low MCPH1/BRIT1 samples, 
only in high MCPH1/BRIT1 expression samples ((p=0.02); Fig. 4F) and 
(p=0.02;  4G 1R VLJQLILFDQW GLIIHUHQFH LQ WKH  SHUFHQWDJH RI Įȕ- hTERT 
expression in samples with low or high MCPH1/BRIT1 expression was 
identified (data not shown). We did not observe any statistical differences 
between hTERT variants (absolute and relative expression values) and 
MCPH1/BRIT1 in primary cultures (data not shown). The correlation between 
high MCPH1/BRIT1 expression DQG Į-ȕ hTERT expression was further 
supported XVLQJ Į-/ȕ hTERT constructs in cancer cell lines. We observed 
increased MCPH1/BRIT1 expression in 3/5 (67%) of cell lines transfected with 
an Į-/ȕ hTERT construct (Fig. 4H). These findings confirm our observations 
in EOC tissues. 
 
3.5 Comparison of hTERT splicing variants with BRCA1 expression  
Similar to MCPH1/BRIT1, BRCA1 expression was correlated with 
absolute and relative values of hTERT splice variants in EOC tissues. We 
found that 6/7 samples expressing low levels of BRCA1 ZHUHQHJDWLYHIRUĮ-
ȕhTERT expression (p=0.003; Fig. 5A). Samples with low levels of BRCA1 
were also negative for Į-ȕ- hTERT expression; however, this association was 
not significant (p=0.09; Fig. 5B). No association was identified between the 
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DEVROXWHYDOXHRIĮȕ RUĮȕ- hTERT expression and BRCA1 levels (data 
not shownĮȕhTERT was expressed at a higher percentage in samples 
with low BRCA1 expression compared with samples with high BRCA1 
expression (Fig. 5C). A high percentage of Į-ȕ hTERT expression was 
identified in samples with high BRCA1 expression. Similarly 6/7 low BRCA1 
expressing tissue VDPSOHVGLGQRWH[SUHVVĮ-ȕhTERT (p=0.003; Fig. 5D). 
The relative H[SUHVVLRQRIRIĮ-ȕ- hTERT was positively correlated with high 
BRCA1 expression and not detected in tissues expressing low BRCA1 
(p=0.04; Fig. 5E). A reverse trend was identified in the correlation of the 
SHUFHQWDJH RI Įȕ hTERT with BRCA1 expression, which did not reach 
statistical significance (p=0.1; Fig. 5F). No significant association between the 
SHUFHQWDJH RI Įȕ- hTERT and BRCA1 expression was found (data not 
shown).  
 
3.6 Correlation of hTERT expression with clinical prognostic factors  
We did not identify any correlations between total hTERT and hTERT 
splice variants with tumor stage, grade and histology in either EOC tissues or 
primary cultures (data not shown). Furthermore, we did not observe any 
changes in survival time between positive and negative total hTERT in EOC 
tissues or primary cultures (data not shown). Interestingly, analysis of survival 
data after grouping positive samples into low and high hTERT levels based on 
the mean expression showed that patients with no or low total hTERT had 
comparable survival times, and that they had significantly longer survival 
times than patients with high hTERT expression in primary EOC cultures 
(q=0.04; Fig. 6A). A similar trend was observed in the EOC tissue although 
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this did not reach statistical significance (q=0.1). After excluding patients who 
were negative for total hTERT expression, we observed an association 
between total hTERT expression and survival; patients with high total hTERT 
expression had shorter survival times than patients with low total hTERT 
expression in primary EOC cultures (q=0.02; Fig. 6B). A similar trend was 
observed in the EOC tissue although this did not reach statistical significance 
(q=0.1). Generally, hTERT splicing did not show significant changes with 
survival. However, patients who expressed Į+ȕ- hTERT in primary EOC 
culture samples showed a longer survival period compared to those that did 
not (q=0.0003; Fig 6C). 
 
4. Discussion 
The aim of this study was to evaluate the expression of hTERT splice 
variants in EOC tissues and primary EOC cultures. We assessed the 
expression of 4 H[RQĮDQGȕhTERT variants ĮȕĮ-ȕĮȕ- DQGĮ-ȕ-), 
previously identified in melanoma, thyroid and cervical cancer [25,8,26]. Other 
possible hTERT variants, such as WKH Ȗ- deletion or exon 2 deletions [27], 
were not examined here. We then correlated hTERT splice variant expression 
with expression of MCPH1/BRIT1 and BRCA1, which are hTERT negative 
regulators in EOC. To our knowledge this is the first study that evaluates 
correlations between the expression levels of the hTERT regulators MCPH1 
and BRCA1, hTERT variant expression and telomerase activity.  
We initially characterised telomerase activity and the expression of 4 
hTERT splice variants in ovarian cancer cell lines. Similarly to a recent study 
by Khosravi and colleagues, we found that the cell lines expressed a mixed 
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pattern of all 4 hTERT variants [28]. There was a higher level of expression 
for Į-ȕhTERT compared to WKHĮȕ-DQGĮ-ȕ- hTERT variants. Similarly, 
a lung adenocarcinoma cell line study demonstrated greater expression of the 
Į-ȕ hTERT variant compared to Įȕ- and Į-ȕ hTERT variants [29]. In 
contrast, WKHĮ-ȕhTERT variant accounted for only 1% of the total hTERT in 
a panel of cell lines originating from different organs [24]. Such contradictory 
findings may indicate that the Į-ȕ DQG Įȕ- hTERT variants have little 
impact on overall telomerase activity in a variety of cell lines.  
No correlation was identified between the expression levels of the 
different hTERT splice variants and telomerase activity in the ovarian cancer 
cell lines. Potentially other mechanisms may contribute to the regulation of 
telomerase such as post transcriptional factors like phosphorylation or the 
presence of telomerase inhibitors or activators such as protein phosphatase 
2A or Akt kinase respectively [30-31]. Another possible explanation for these 
findings may be that the regulation of telomerase activity by hTERT splice 
variants is tumour-specific and that there could be additional splice variants 
present in ovarian cancer cell lines that were not investigated in this study 
[32]. 
Our study indicates that MCPH1/BRIT1 functions as a negative 
regulator of total hTERT activity in EOC tissues and primary cultures, in 
samples expressing high or low total hTERT. In terms of hTERT variants, 
Įȕ hTERT and MCPH1/BRIT1 expression were found to be associated; 
MCPH1/BRIT1 expression was diminished in EOC tissue samples that 
H[SUHVVHGKLJKĮȕhTERT. For BRCA1 expression, no major difference in 
the samples showing low or high total hTERT in either EOC tissues or primary 
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cultures was observed. The correlation of BRCA1 with hTERT alternate splice 
variants only revealed a trend between BRCA1 DQGĮȕhTERT expression 
in EOC tissues. In samples with no hTERT activity we observed no negative 
regulation of BRCA1 and MCPH1/BRIT1. When samples were grouped into 
positive and negative total hTERT activity, those with negative activity 
demonstrated low levels of MCPH1/BRIT1 expression in EOC tissues 
(p=0.01) and primary cultures (p=0.10). Similarly, samples with negative total 
hTERT demonstrated low levels of BRCA1 expression in primary culture 
compared to positive total hTERT samples (p=0.04). Taken together, these 
findings indicate that BRCA1 and MCPH1/BRIT1 have adverse regulatory 
effects on the expression of hTERT only when samples are positive for 
hTERT expression.  
Previously, BRCA1 siRNA knockdown in T47D, MCF-7 and DU-145 
cell lines was found to increase hTERT mRNA expression and telomerase 
activity [33]. Taking that study together with our findings, we propose that 
MCPH1/BRIT1 and BRCA1 might act as tumor suppressors via the negative 
regulation of hTERT. Furthermore, our findings indicate that decreased 
MCPH1/BRIT1 expression may increase the levels and/or the activity of 
telomerase.  
The most commonly identified dominant negative regulator of 
telomerase activity in both EOC tissue samples and primary cultures was the 
Įȕ- hTERT splice variant,  consistent with previous studies that identified a 
QHJDWLYH FRUUHODWLRQ EHWZHHQ WHORPHUDVH DFWLYLW\ DQG UHODWLYH Įȕ- hTERT 
expression in melanoma and lung cancer [25,29]. In our study, relative and 
DEVROXWH H[SUHVVLRQ RI Įȕ- hTERT were not associated with BRCA1 or 
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MCPH1/BRIT1 in EOC tissue or primary cultures. Conversely, there was a 
positive correlation of Į-ȕhTERT DQGĮ-ȕ- hTERT with both MCPH1/BRIT1 
and BRCA1 in their absolute, as well as their relative, levels of hTERT 
H[SUHVVLRQ$Į-ȕhTERT plasmid construct confirmed this correlation in cell 
lines. A previous study had also shown decreased telomerase activity 
following transfection with an Į-ȕhTERT plasmid construct [21].  
The value of hTERT expression as a prognostic biomarker remains 
controversial. An association between hTERT and tumor stage has been 
reported in bladder cancer [34] and tumour grade in breast cancer [35]. In 
contrast hTERT was not a prognostic marker in lung cancer [29] or gastric 
cancer [36]. Furthermore, the role of hTERT mRNA splicing in the regulation 
of telomerase activity remains unclear. The utility of hTERT gene products in 
clinical diagnostics therefore remains uncertain.  
hTERT has been considered an important predictor of survival. Shorter 
survival was observed in hTERT-positive patients with non-small cell lung 
cancer [37] and pediatric intracranial ependymoma [38]. In our samples, a 
simple positive and negative hTERT expression classification did not correlate 
with survival. However, an association with survival was identified by classing 
total hTERT as either high or low in primary EOC primary cultures and a trend 
in the the tissue samples. Patients with a low total hTERT expression had a 
longer life span. Potentially the higher sensitivity of the method used in our 
study could account for the conflict with results from previous studies. It is 
possible that we could detect a lower level of total hTERT expression using 
the TaqMan qRT-PCR assay compared to the immunohistochemistry [37] or 
in situ hybridization [38] used in earlier studies. Further research on a larger 
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sample size would be required for this potentially important observation to be 
confirmed. 
In conclusion, the negative association between MCPH1/BRIT1 and 
the functional form of hTERT Įȕ) supports its role as a negative regulator 
of telomerase activity in primary EOC samples.  
 
Conflict of interest 
The authors declare that they have no conflict of interest. 
 
Acknowledgements 
We are grateful to all participants of this research study. The Į-ȕhTERT 
construct was kindly provided by Professor RR Reddel (Children's Medical 
Research Institute, University of Sydney, Australia). RA was supported by a 
scholarship from the Saudi Arabian government. 
 
$XWKRUV¶UROHV 
R.A. J.B. E.E.M and S.M.B designed the study. R.A. and S.M.B. drafted the 
manuscript and prepared the figures. R.A. and A.B-R performed the 
experiments. S.C.B. and S.A.B developed the Telomerase and hTERT splice 
variant real-time assays. R.H. and N.G. provided tissue samples and clinical 
data. S.C.B, J.B, E.E.M. and S.A.B. assisted in drafting the manuscript and 
figures. All authors read and critically revised the manuscript and provided 
their final approval before submission. 
 
Figure legends 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 20 
Fig. 1. hTERT splice variant expression in ovarian cancer cell lines  
(A) Absolute (fold change) and (B) relative (percentage) hTERT splice variant 
expression in the ovarian cancer cell lines OVCA433, SKOV-3, TR175 and 
 ([SUHVVLRQ RI Į-ȕ KTERT ZDV KLJKHU WKDQ WKH H[SUHVVLRQ RI Įȕ- 
DQG Į-ȕ- hTERT. Bars represent the average expression of hTERT splice 
variants in the cell lines. 
 
Fig. 2. mRNA expressions of total hTERT, hTERT splice variants, 
MCPH1/BRIT1 and BRCA1 in EOC tissues and primary cultures 
For all graphs the mean value, is depicted by a red dotted line and was used 
to separate the samples into high and low expression (A) Total hTERT 
expression in EOC tissues (n=15). Benign samples are highlighted in the blue 
box, and one normal ovary tissue sample is shown in red. (B) Total hTERT 
expression in the primary EOC culture samples. (C) Detection of hTERT 
variants in EOC tissues. (D) Detection of hTERT variants in primary EOC 
cultures. (E) MCPH1/BRIT1 expression in EOC tissues ranged from a 0.011- 
to 1.83-fold change (Relative to fetal brain standard curve). (F) MCPH1/BRIT1 
expression in primary EOC cultures ranged from a 0.003- to 5.26-fold change. 
(G) BRCA1 expression in EOC tissues ranged from a 0.363- to 37.3-fold 
change (Relative to normal ovary standard curve). (H) BRCA1 expression in 
primary EOC cultures ranged from a 0.01- to 17.38-fold change. 
 
Fig. 3. Correlation of total hTERT with MCPH1/BRIT1 and BRCA1 
expression in EOC tissues and primary cultures 
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(A) In EOC tissues, a significant negative correlation between MCPH1/BRIT1 
and total hTERT was identified in positive total hTERT samples (p=0.05). 
Samples with negative total hTERT exhibited low MCPH1/BRIT1 when 
compared to samples which expressed total hTERT (p=0.01). (B) In EOC 
cultures, MCPH1/BRIT1 and total hTERT showed same pattern of 
association, such that sample with low total hTERT demonstrated high levels 
of MCPH1/BRIT1 in total hTERT positive samples (p=0.03). Samples with 
negative total hTERT showed low levels of MCPH1/BRIT1 when compared 
with samples with positive total hTERT, however, this did not reach statistical 
significant (p=0.10). (C) In EOC tissue samples, no association was identified 
between BRCA1 and total hTERT. (D) In EOC culture samples high BRCA1 
expression was identified in patients exhibiting positive total hTERT 
expression, when compared to samples that did not expressed total hTERT 
expression (p=0.04). However, no difference in BRCA1 expression was 
identified between low and high total hTERT expression (p=0.83) (MW).  
 
Fig. 4. MCPH1/BRIT1 and hTERT splice variant expression in EOC 
tissues and primary cultures 
MCPH1/BRIT1 was correlated with absolute (A-C) and relative expression (D-
G) of hTERT variants. (A) Samples with low MCPH1/BRIT1 expression 
VKRZHGKLJKHUĮȕhTERT compared to samples with high MCPH1/BRIT1 
(p=0.04)%RWKĮ-ȕ%DQGĮ-ȕ- hTERT (C) were positively correlated with 
MCPH1/BRIT1 (p=0.02). (D) MCPH1/BRIT1 expression decreased in 
VDPSOHVH[FOXVLYHO\H[SUHVVLQJĮȕRUĮȕDQGĮȕ- hTERT. While, high 
MCPH1/BRIT1 H[SUHVVLRQ VDPSOHV GHPRQVWUDWHG WKH H[SUHVVLRQ RI Į-ȕ
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DQGRU Į-ȕ- hTERT. (E) $ KLJK SHUFHQWDJH RI Įȕ hTERT, ranging from 
39% to 100%, with a mean of 71%, was identified in low MCPH1/BRIT1 
expression samples compared with the mean of 23% in high MCPH1/BRIT1 
expression samples (p=0.01). (F) No  Į-ȕ hTERT expression was detected 
in low MCPH1/BRIT1 samples, in comparison to the elevated mean of 30% 
(p=0.02) for Į-ȕ in high MCPH1/BRIT1 expression samples. (G) 1R Į-ȕ- 
hTERT expression was detected in low MCPH1/BRIT1 samples, in 
comparison to the elevated mean of 27% (p=0.02) for Į-ȕ- hTERT in high 
MCPH1/BRIT1 expression samples. (H) Demonstrated MCPH1/BRIT1 
H[SUHVVLRQ LQ FHOO OLQHV WUDQVIHFWHG ZLWK Į-ȕ+ hTERT construct. 
MCPH1/BRIT1 expression increased in 3 FHOO OLQHV WUDQVIHFWHG ZLWK Į-ȕ
hTERT compared to their matched untransfected control cells (HEK 293, 
SKOV-3 and 1847). 2/5 cell lines (TR175 and OVCA433) did not showed the 
positive correlation between MCPH1/BRIT1 and Į-/ȕ hTERT expression.  
 
Fig. 5. BRCA1 and hTERT splice variant expression in EOC tissues 
BRCA1 was correlated with absolute (A-B) and relative expression of hTERT 
variants (C-F). (A) BRCA1 expression was positively correlated with Į-ȕ
hTERT expression (p=%7KHH[SUHVVLRQRIWKHĮ-ȕ- hTERT also had 
a weak positive correlation with BRCA1 expression (p=0.09). (C) Correlation 
between BRCA1 expression and each hTERT isoform related to other 
isoforms([SUHVVLRQRIĮ-ȕDQGĮ-ȕ- hTERT was more frequent in samples 
expressing high BRCA1. (D-E 3HUFHQWDJH RI Į-ȕ DQG Į-ȕ- hTERT 
expression was strongly correlated with BRCA1 expression (p=0.003 and p= 
0.04 respectively). (F) A weak negative association was detected between low 
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Įȕ hTERT expression and high BRCA1 H[SUHVVLRQ DQG KLJK Įȕ
hTERT with with low BRCA1 expression (p=0.1) (MW). 
 
Fig. 6. Patient Kaplan-Meir survival plots of hTERT expression in EOC 
tissues and primary cultures 
Grouping positive total hTERT expression samples into low and high 
categories based on the mean expression showed that patients with low and 
negative total hTERT have comparable survival times and high total hTERT 
patients have a shorter survival time compared to patients with no or low total 
hTERT expression in (A) primary EOC cultures (q=0.04). Further analysis 
after excluding patients who did not expressed total hTERT revealed that 
patients with low total hTERT have longer survival time compared to patients 
with high total hTERT in (B) primary EOC cultures (q=0.02). (C) Splice variant 
analysis in primary EOC cultures idenfied increased survival times in patients 
with low Įȕ- expression compared to patients with high expression 
(q=0.0004). 
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Abbreviations 
 
BRIT1 - BRCT-repeat inhibitor of hTERT expression  
cDNA - complementary DNA   
DTT - dithiothreitol 
EOC - Epithelial ovarian cancer  
hTERT ± human Telomerase reverse transcriptase 
MW - Mann-Whitney 
OCT - Optimal cutting temperature  
qRT- PCR ± Quantitative reverse transcriptase polymerase chain reaction 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 30 
Highlights 
 
x High total hTERT expression was associated with low MCPH1/BRIT1 
expression.  
 
x A strong positive association between MCPH1/BRIT1 and ERWK Į-/ȕ 
and Į-/ȕ- hTERT.  
 
x A negative association between MCPH1/BRIT1 and the functional form 
of hTERT Įȕ.  
 
x A positive association between BRCA1 and Į-/ȕ hTERT and Į-/ȕ- 
hTERT expression.  
 
x These findings support a regulatory effect of MCPH1/BRIT1 and 
BRCA1 on telomerase activity. 
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